美股期權個股詳情

PGNY240517C20000 

添加自選
  • 7.30
  • -0.75-9.32%
延時15分鐘行情收盤價 05/17 15:59 (美東)
7.30最高價7.30最低價
分時
  • 5日
  • 日K

評論

    $Progyny(PGNY.US)$ 就喜歡抄底不追高
    已翻譯
    Progyny's CEO, Pete Anevski, is thrilled about the executive team expansion, confident that the new members' expertise will boost the company's growth in fertility, family building, and women's health benefits. Both Higgins and Leist are excited to contribute to Progyny's growth and innovation.
    Investors may be justifying Progyny's high P/E ratio by betting on its potential to outperform market growth. The company's strong forecast growth is believed to be upholding its high P/E and providing strong support to its share price.
    Progyny, with a low ROCE score of 9.2%, underscores promising fundamentals following its foray into profitability. Having offered a notable 27% to shareholders over three years, its developing factors necessitate a deeper analysis for future investment opportunities.
    $Progyny(PGNY.US)$2019年上市,上市後營收連續高速增長,近3年平均增速達到51%,營業利潤受費用高速增長影響,在2020和2022年均有下滑,近3年平均增速爲34.1%,淨利潤2022年萎縮54%,低於2020年的水平。
    2023上半年營收增長46.4%,營業利潤受費用增速放緩影響增長2.4倍達到0.3億,淨利潤增長1.4倍達到0.33億。
    資產負債表顯示最近3年應收帳款增加了1.9億,而3年累計淨利潤僅有1.4億,應收帳款2.4億也達到了年營收的30.5%,比例偏高。負債率31.1%,沒有有息負債。
    近3年現金流經營淨額高於投資淨額,產生了一定股東盈餘。
    目前市盈率109,市盈率TTM66.8,如果全年淨利達到0.7億,市盈率將下降到44.6,可以再觀察幾個季度。
    已翻譯
閱讀更多